{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:46Z","timestamp":1792785946812,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Agency for Medical Research and Development","award":["JP21fk0108427"],"award-info":[{"award-number":["JP21fk0108427"]}]},{"name":"Agency for Medical Research and Development","award":["JP21fk0108589"],"award-info":[{"award-number":["JP21fk0108589"]}]},{"name":"Agency for Medical Research and Development","award":["JP22fk0310504"],"award-info":[{"award-number":["JP22fk0310504"]}]},{"name":"Agency for Medical Research and Development","award":["JP22jm0210068"],"award-info":[{"award-number":["JP22jm0210068"]}]},{"name":"Agency for Medical Research and Development","award":["JP20wm0325007"],"award-info":[{"award-number":["JP20wm0325007"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03499"],"award-info":[{"award-number":["JP20H03499"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJMI22G1"],"award-info":[{"award-number":["JPMJMI22G1"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJMS2021"],"award-info":[{"award-number":["JPMJMS2021"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJMS2025"],"award-info":[{"award-number":["JPMJMS2025"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mpox virus (MPXV) is a zoonotic orthopoxvirus and caused an outbreak in 2022. Although tecovirimat and brincidofovir are approved as anti-smallpox drugs, their effects in mpox patients have not been well documented. In this study, by a drug repurposing approach, we identified potential drug candidates for treating mpox and predicted their clinical impacts by mathematical modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We screened 132 approved drugs using an MPXV infection cell system. We quantified antiviral activities of potential drug candidates by measuring intracellular viral DNA and analyzed the modes of action by time-of-addition assay and electron microscopic analysis. We further predicted the efficacy of drugs under clinical concentrations by mathematical simulation and examined combination treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Atovaquone, mefloquine, and molnupiravir exhibited anti-MPXV activity, with 50% inhibitory concentrations of 0.51\u20135.2 \u03bcM, which was more potent than cidofovir. Whereas mefloquine was suggested to inhibit viral entry, atovaquone and molnupiravir targeted postentry processes. Atovaquone was suggested to exert its activity through inhibiting dihydroorotate dehydrogenase. Combining atovaquone with tecovirimat enhanced the anti-MPXV effect of tecovirimat. Quantitative mathematical simulations predicted that atovaquone can promote viral clearance in patients by 7 days at clinically relevant drug concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data suggest that atovaquone would be a potential candidate for treating mpox.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiad058","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T10:39:44Z","timestamp":1678358384000},"page":"591-603","source":"Crossref","is-referenced-by-count":28,"title":["Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments"],"prefix":"10.1093","volume":"228","author":[{"given":"Daisuke","family":"Akazawa","sequence":"first","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hishiki","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoya","family":"Iwanami","sequence":"additional","affiliation":[{"name":"Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University , Nagoya , Japan"},{"name":"Department of Science System Simulation, Pukyong National University , Busan , South Korea"},{"name":"Department of Mathematics, Pusan National University , Busan , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Dam","family":"Jeong","sequence":"additional","affiliation":[{"name":"Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University , Nagoya , Japan"},{"name":"Department of Mathematics, Pusan National University , Busan , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Sil","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Veterinary Science, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyo","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Shionoya","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases , Tokyo , Japan"},{"name":"Department of Applied Biological Science, Tokyo University of Science , Noda , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mifune","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Tsuchimoto","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjiro","family":"Ojima","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aa Haeruman","family":"Azam","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeongki","family":"Park","sequence":"additional","affiliation":[{"name":"Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University , Nagoya , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Virology I, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shimojima","sequence":"additional","affiliation":[{"name":"Department of Virology I, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Kiga","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Iwami","sequence":"additional","affiliation":[{"name":"Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University , Nagoya , Japan"},{"name":"Institute of Mathematics for Industry, Kyushu University , Fukuoka , Japan"},{"name":"Institute for the Advanced Study of Human Biology, Kyoto University , Kyoto , Japan"},{"name":"Interdisciplinary Theoretical and Mathematical Sciences Program, RIKEN , Saitama , Japan"},{"name":"NEXT-Ganken Program, Japanese Foundation for Cancer Research , Tokyo , Japan"},{"name":"Science Groove, Inc , Fukuoka , Japan"},{"name":"MIRAI, Japan Science and Technology Agency , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Veterinary Science, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ebihara","sequence":"additional","affiliation":[{"name":"Department of Virology I, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[{"name":"Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases , Tokyo , Japan"},{"name":"Interdisciplinary Biology Laboratory, Graduate School of Science, Nagoya University , Nagoya , Japan"},{"name":"Department of Virology II, National Institute of Infectious Diseases , Tokyo , Japan"},{"name":"Department of Applied Biological Science, Tokyo University of Science , Noda , Japan"},{"name":"MIRAI, Japan Science and Technology Agency , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"2023083107440683900_jiad058-B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41586-022-01421-8","article-title":"Monkeypox goes global: why scientists are on alert","volume":"606","author":"Kozlov","year":"2022","journal-title":"Nature"},{"key":"2023083107440683900_jiad058-B2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox virus infection in humans across 16 countries\u2014April-June 2022","volume":"387","author":"Thornhill","year":"2022","journal-title":"N Engl J Med"},{"key":"2023083107440683900_jiad058-B3","first-page":"433","article-title":"Neglecting emerging diseases\u2014monkeypox is the latest price of a costly default","volume":"3","author":"Titanji","year":"2022","journal-title":"Med (N Y)"},{"key":"2023083107440683900_jiad058-B4","author":"Centers for Disease Control and Prevention"},{"key":"2023083107440683900_jiad058-B5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01683-19","article-title":"Drug development against smallpox: present and future","volume":"64","author":"Delaune","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jac\/dku545","article-title":"ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping","volume":"70","author":"Duraffour","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023083107440683900_jiad058-B7","article-title":"Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model","volume":"6","author":"Hutson","year":"2021","journal-title":"mSphere"},{"key":"2023083107440683900_jiad058-B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antiviral Res"},{"key":"2023083107440683900_jiad058-B9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023083107440683900_jiad058-B10","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1099\/vir.0.010207-0","article-title":"Virulence and pathophysiology of the Congo basin and west African strains of monkeypox virus in non-human primates","volume":"90","author":"Saijo","year":"2009","journal-title":"J Gen Virol"},{"key":"2023083107440683900_jiad058-B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2018.05.010","article-title":"Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP)","volume":"156","author":"Bauer","year":"2018","journal-title":"Antiviral Res"},{"key":"2023083107440683900_jiad058-B12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbrc.2020.10.042","article-title":"The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2?","volume":"538","author":"Jans","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2023083107440683900_jiad058-B13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"2023083107440683900_jiad058-B14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"2023083107440683900_jiad058-B16","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"key":"2023083107440683900_jiad058-B17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1600-0854.2005.00324.x","article-title":"Cytoplasmic organization of poxvirus DNA replication","volume":"6","author":"Schramm","year":"2005","journal-title":"Traffic"},{"key":"2023083107440683900_jiad058-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102367","article-title":"Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment","volume":"24","author":"Ohashi","year":"2021","journal-title":"iScience"},{"key":"2023083107440683900_jiad058-B19","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.651403","article-title":"Mefloquine, a potent anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) drug as an entry inhibitor","volume":"12","author":"Shionoya","year":"2021","journal-title":"Front Microbiol"},{"key":"2023083107440683900_jiad058-B20","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1128\/JVI.73.11.9098-9109.1999","article-title":"Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus","volume":"73","author":"V\u00e1zquez","year":"1999","journal-title":"J Virol"},{"key":"2023083107440683900_jiad058-B21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res"},{"key":"2023083107440683900_jiad058-B22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3851\/IMP2229","article-title":"Antiviral activity of nucleoside analogues against norovirus","volume":"17","author":"Costantini","year":"2012","journal-title":"Antivir Ther"},{"key":"2023083107440683900_jiad058-B23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of \u03b2-d-N4-hydroxycytidine as a novel inhibitor of chikungunya virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"2023083107440683900_jiad058-B25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B26","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1038\/ncomms5029","article-title":"Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action","volume":"5","author":"Birth","year":"2014","journal-title":"Nat Commun"},{"key":"2023083107440683900_jiad058-B27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1128\/AAC.02347-14","article-title":"Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor","volume":"59","author":"Guler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/v14050928","article-title":"A broad antiviral strategy: inhibitors of human DHODH pave the way for host-targeting antivirals against emerging and re-emerging viruses","volume":"14","author":"Zheng","year":"2022","journal-title":"Viruses"},{"key":"2023083107440683900_jiad058-B29","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","article-title":"The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase","volume":"35","author":"Davis","year":"1996","journal-title":"Biochemistry"},{"key":"2023083107440683900_jiad058-B30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1716255114","article-title":"Enigmatic origin of the poxvirus membrane from the endoplasmic reticulum shown by 3D imaging of vaccinia virus assembly mutants","volume":"114","author":"Weisberg","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023083107440683900_jiad058-B31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"key":"2023083107440683900_jiad058-B32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B33","author":"GlaxoSmithKline"},{"key":"2023083107440683900_jiad058-B34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2875-8-58","article-title":"Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria","volume":"8","author":"Gutman","year":"2009","journal-title":"Malar J"},{"key":"2023083107440683900_jiad058-B35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023083107440683900_jiad058-B36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001128","article-title":"A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2","volume":"19","author":"Kim","year":"2021","journal-title":"PLoS Biol"},{"key":"2023083107440683900_jiad058-B37","article-title":"Clinical characterization of human monkeypox infections in the democratic republic of the Congo","author":"Pittman","year":"2022","journal-title":"medRxiv"},{"key":"2023083107440683900_jiad058-B38","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1073\/pnas.1610197114","article-title":"Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection","volume":"114","author":"Koizumi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023083107440683900_jiad058-B39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat Med"},{"key":"2023083107440683900_jiad058-B40","first-page":"331","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol Rev"},{"key":"2023083107440683900_jiad058-B41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1742-4682-11-41","article-title":"Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs","volume":"11","author":"Koizumi","year":"2014","journal-title":"Theor Biol Med Model"},{"key":"2023083107440683900_jiad058-B42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003660","article-title":"Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: a modeling study","volume":"18","author":"Iwanami","year":"2021","journal-title":"PLoS Med"},{"key":"2023083107440683900_jiad058-B43","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006491.pub2","article-title":"Drugs for preventing malaria in travellers","volume":"(4)","author":"Jacquerioz","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2023083107440683900_jiad058-B44","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105372","article-title":"Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 omicron subvariants, BA.1 and BA.2","volume":"205","author":"Ohashi","year":"2022","journal-title":"Antiviral Res"},{"key":"2023083107440683900_jiad058-B45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijantimicag.2011.07.002","article-title":"Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture","volume":"38","author":"Schnellrath","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2023083107440683900_jiad058-B46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2125.2005.02415.x","article-title":"Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis","volume":"60","author":"Chan","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"2023083107440683900_jiad058-B47","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/microorganisms10112192","article-title":"Animal models used in monkeypox research","volume":"10","author":"Dom\u00e1n","year":"2022","journal-title":"Microorganisms"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad058\/49767767\/jiad058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/5\/591\/51312850\/jiad058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/5\/591\/51312850\/jiad058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T03:47:00Z","timestamp":1693453620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/5\/591\/7074137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad058","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,3,9]]}}}